oncology-target-validation-execution

Compare original and translation side by side

🇺🇸

Original

English

🇨🇳

Translation

Chinese

Use this skill when the active step is about whether a cancer target is selective, tractable, biomarker-linked, or supported across screening and pharmacology evidence.

Instructions:

Distinguish broad essentiality from selective vulnerability before making a target-quality judgment.
Use screening evidence and compound-response evidence as complementary signals, not substitutes.
Prefer disease-, lineage-, or biomarker-specific interpretation over pan-cancer averages when the question is therapeutic relevance.
If a target appears pan-essential, call that out as a liability unless the user explicitly wants broad essential genes.
Do not present aggregate DepMap release-level results as if they were lineage- or mutation-filtered evidence. If the available tool cannot provide the requested subtype slice, state that limitation explicitly instead of forcing specificity.
Treat
```
get_gdsc_drug_sensitivity
```
,
```
get_prism_repurposing_response
```
, and
```
get_pharmacodb_compound_response
```
as compound-first tools. They need a named drug/compound query and should not be used to discover unknown compounds from model-only prompts.
Load
```
references/oncology-target-validation-execution.md
```
before concluding oncology target-validation steps.

当当前步骤涉及判断癌症靶点是否具有选择性、可靶向性、生物标志物相关性，或是否得到筛选和药理学证据支持时，使用此skill。

说明：

在做出靶点质量判断之前，先区分广泛必要性与选择性脆弱性。
将筛选证据和化合物响应证据视为互补信号，而非替代信号。
当问题涉及治疗相关性时，优先选择针对疾病、谱系或生物标志物的特异性解读，而非泛癌症平均值。
如果某个靶点表现出泛必要性，需将其列为不利因素，除非用户明确需要广泛必要基因。
不要将汇总的DepMap发布级结果当作经过谱系或突变筛选的证据呈现。如果可用工具无法提供所需的亚型细分数据，需明确说明该限制，而非强行给出特异性结果。
将
```
get_gdsc_drug_sensitivity
```
、
```
get_prism_repurposing_response
```
和
```
get_pharmacodb_compound_response
```
视为以化合物为核心的工具。它们需要指定药物/化合物查询，不应仅根据模型提示来发现未知化合物。
在完成肿瘤靶点验证步骤之前，加载
```
references/oncology-target-validation-execution.md
```
文档。